FENNEC PHARMACEUTICALS INC.: operating income or loss
Operating income or loss for FENNEC PHARMACEUTICALS INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All FENNEC PHARMACEUTICALS INC. financial histories
What this measure means
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
Exact concept: us-gaap:OperatingIncomeLoss. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2010-01-01 to 2025-12-31. The SEC response was captured on 2026-09-19.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -6,282,000 | USD | 2026-03-27 | 10-K · 0001104659-26-036182 |
| 2024-01-01 | 2024-12-31 | 2,568,000 | USD | 2026-03-27 | 10-K · 0001104659-26-036182 |
| 2023-01-01 | 2023-12-31 | -12,771,000 | USD | 2025-03-26 | 10-K · 0001558370-25-003710 |
| 2022-01-01 | 2022-12-31 | -22,589,000 | USD | 2024-03-29 | 10-K · 0001558370-24-004383 |
| 2021-01-01 | 2021-12-31 | -17,223,000 | USD | 2023-03-29 | 10-K · 0001558370-23-004948 |
| 2020-01-01 | 2020-12-31 | -17,885,000 | USD | 2022-02-28 | 10-K · 0001558370-22-002334 |
| 2019-01-01 | 2019-12-31 | -13,009,000 | USD | 2021-03-30 | 10-K · 0001104659-21-043756 |
| 2018-01-01 | 2018-12-31 | -10,409,000 | USD | 2020-02-14 | 10-K · 0001104659-20-021132 |
| 2017-01-01 | 2017-12-31 | -6,951,000 | USD | 2019-03-15 | 10-K · 0001144204-19-014220 |
| 2016-01-01 | 2016-12-31 | -2,871,000 | USD | 2018-03-28 | 10-K · 0001144204-18-017571 |
| 2015-01-01 | 2015-12-31 | -1,890,000 | USD | 2017-03-29 | 10-K · 0001144204-17-017299 |
| 2014-01-01 | 2014-12-31 | -2,877,000 | USD | 2016-03-28 | 10-K · 0001144204-16-090604 |
| 2013-01-01 | 2013-12-31 | -1,931,000 | USD | 2015-03-31 | 10-K · 0001144204-15-020272 |
| 2012-01-01 | 2012-12-31 | -3,620,000 | USD | 2014-03-31 | 10-K · 0001144204-14-019399 |
| 2011-01-01 | 2011-12-31 | -3,438,000 | USD | 2013-04-01 | 10-K · 0001144204-13-019057 |
| 2010-01-01 | 2010-12-31 | -4,604,000 | USD | 2012-03-27 | 10-K · 0001144204-12-017470 |
Related financial histories
- FENNEC PHARMACEUTICALS INC.: total assets
- FENNEC PHARMACEUTICALS INC.: total liabilities
- FENNEC PHARMACEUTICALS INC.: stockholders equity
- FENNEC PHARMACEUTICALS INC.: cash and cash equivalents
- FENNEC PHARMACEUTICALS INC.: net income or loss
- FENNEC PHARMACEUTICALS INC.: operating cash flow
- FENNEC PHARMACEUTICALS INC.: capital expenditure payments
- FENNEC PHARMACEUTICALS INC.: revenue
- FENNEC PHARMACEUTICALS INC.: financing cash flow
- FENNEC PHARMACEUTICALS INC.: retained earnings or deficit
- FENNEC PHARMACEUTICALS INC.: basic weighted-average shares
- FENNEC PHARMACEUTICALS INC.: diluted weighted-average shares
- FENNEC PHARMACEUTICALS INC.: basic earnings per share
- FENNEC PHARMACEUTICALS INC.: diluted earnings per share
- FENNEC PHARMACEUTICALS INC.: income tax expense or benefit
- FENNEC PHARMACEUTICALS INC.: share-based compensation expense
- FENNEC PHARMACEUTICALS INC.: current assets
- FENNEC PHARMACEUTICALS INC.: current liabilities
- FENNEC PHARMACEUTICALS INC.: current accounts payable
- FENNEC PHARMACEUTICALS INC.: operating expenses
- FENNEC PHARMACEUTICALS INC.: research and development expense
Inspect the source
- Entity
- FENNEC PHARMACEUTICALS INC. / CIK 0001211583
- Captured
- 2026-09-19T11:17:02.352Z
- SEC response SHA-256
f5de26e280e9814def3db187bfe6961cb26c6e601a5f986375859c81818e8ab8
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001211583.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))